Caplight Directory>Companies>Kailera Therapeutics-preview>Kailera-therapeutics


Kailera Therapeutics

Kailera Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceswww.kailera.com

Last Round

IPO

4/20/2026

Est. Valuation

$3.1B

Total Funding Raised

$1B

Momentum Score

25 /100

Company Overview

Kailera Therapeutics is a biopharmaceutical company focused on providing innovative treatment options for obesity and related conditions through a diverse range of clinical-stage injectable and oral therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

obesity therapiesGLP-1/GIP dual agonistweight loss drugsGLP-1 receptor agonistoral GLP-1chronic weight managementGLP-1 drugsmetabolic disease drugsinjectable GLP-1GIP receptor agonistweight loss shotsGLP-1/GIP/glucagon tri-agonistclinical-stage biopharmatype 2 diabetes treatmentsmall molecule GLP-1drug in-licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kailera Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kailera Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
IPO4/20/2026
Series B10/14/2025
Series A10/1/2024
View all Funding Rounds

Key People

Founding team and executive leadership

Daniela Vincent

Administrative Manager, Office Of The CEO

Executive Team

Ron Renaud

President CEO

Executive Team

Doug Bakan

Chief Technology Officer

Executive Team

Paul Burgess

Chief Operating Officer And Chief Business Officer

Executive Team

View all key people

Kailera Therapeutics Investors

Notable investors and investment history

InvestorRounds
Sirona CapitalSeries B
JefferiesIPO
Surveyor CapitalSeries B
CPP InvestmentsSeries B
Evercore ISIIPO
Bain Capital Life SciencesSeries B, Series A
Janus Henderson GroupSeries B
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    $100M IPO round completed.

  • Jan 5, 2026

    Doug Pagán appointed as Chief Financial Officer.

View all signals

Kailera Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kailera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kailera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range153
Year Founded2013
Last Funding4/20/2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.